Recruiting
Phase 2

HPV Vaccine, Imiquimod, Metformin

Sponsor:

Baylor College of Medicine

Code:

NCT06686043

Conditions

Cervical Carcinoma

Vaginal Carcinoma

Vulvar Carcinoma

HPV (Human Papillomavirus)-Associated Carcinoma

Eligibility Criteria

Sex: Female

Age: 18 - 64

Healthy Volunteers: Not accepted

Interventions

HPV vaccine, Imiquimod, and metformin combination therapy

Study Details

Brief summary:

The goal of this clinical trial is to explore whether additional treatments can help strengthen the participant's immune system to fight cancer caused by the Human Papillomavirus (HPV), a virus spread through intimate skin-to-skin contact. The trial will also monitor the safety of these treatments. The main questions it aims to answer are:

Does the combination of treatments help the participant's body fight the cancer more effectively when used alongside standard therapy? What side effects or medical issues arise when using these experimental treatments? Researchers will use three experimental therapies along with the participant's standard treatment to find out if these therapies work better together than standard treatment alone.

Participants will:

Receive HPV vaccinations during the 2nd and 4th week of radiation, and again at weeks 8, 10, 12, and 16 after completing radiation.

Have blood samples taken, tumor cells brushed from the surface, and imiquimod cream applied during each visit.

Take a daily metformin pill and apply an imiquimod suppository three times a week for two weeks after each visit.

Conditions

Cervical Carcinoma

Vaginal Carcinoma

Vulvar Carcinoma

HPV (Human Papillomavirus)-Associated Carcinoma

Study ID

NCT06686043

Start date

Aug 23, 2024

Status verified date

Nov, 2024

Completion date

Aug 23, 2028

Anticipated

Primary completion date

Aug 23, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 64

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants must have histologically confirmed locally advanced or metastatic cervical carcinoma (Stage IB2-IVB), vaginal, or vulvar carcinoma (Stage II-IVB), AND not be considered a primary surgical candidate. Patients offered neoadjuvant therapy may be enrolled if they respond and receive chemoradiation.
  • Participants must have measurable disease, per Recist criteria. See Section 12 (Measurement of Effect) for the evaluation of measurable disease. Radiological evaluation shall occur within approximately 30 days prior to enrollment initiation and start of radiation.
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  • Participants must be ≥ 18 years of age
  • Participants must have adequate organ function within 28 days of registration, defined as follows: - Absolute neutrophil count ≥ 1,500/µL - Platelets ≥ 100,000/µL - Hemoglobin ≥ 9 g/dL - Serum creatinine ≤ 1.5 x upper limit of normal (ULN) - Total bilirubin ≤ 1.5 x ULN (≤2.0 in patients with known Gilberts syndrome) OR direct bilirubin ≤ 1 x ULN - Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULN
  • Participants receiving corticosteroids may continue as long as their dose is stable for at least 4 weeks prior to initiating protocol therapy.
  • Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment.
  • Female participants of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration. Females of non-childbearing potential is defined as follows (by other than medical reasons): - ≥45 years of age and has not had menses for \>1 year, post-hysterectomy, post-bilateral oophorectomy, post external beam radiation of 6 Gy to the pelvis, or post-tubal ligation.
  • Participants must agree to not breastfeed during the study.
  • Participants must be able to understand the study procedures and agree to participate in the study by providing written informed consent
  • Participants must be eligible for chemoradiation treatment in the opinion of the treating investigator.
  • Participants who are HIV+ must have CD4 counts \>200/dL and demonstrate documented Highly active antiretroviral therapy (HAART) compliance m. Participant must have CT (chest/abdomen/pelvis) or PET-CT, within 56 days of registration.
  • Participants must be newly diagnosed.
  • Standard chemoradiation using external beam radiation therapy (EBRT) and brachytherapy is permitted for cervical or vaginal carcinoma, and chemoradiation with EBRT for vulvar carcinoma. A lesion must be readily accessible for intratumoral tumor injection.
  • ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

Exclusion Criteria:

  • Patients who are receiving any other investigational agents.
  • Patients who have untreated, new or progressive brain metastases or leptomeningeal disease.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study.
  • Patients with uncontrolled intercurrent illness.
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study because cervical carcinoma or vulva carcinoma patients have undergone treatment rendering the patient infertile. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cervical carcinoma or vulva carcinoma, breastfeeding should be discontinued.

Study Design

Enrollment

85 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Treatment group

The treatment group will be compared to a historical control. The investigator will evaluate the immune changes within the tumor microenvironment and validate why the combination immunotherapy study elicited such a robust immune response which led to complete resolution of the cancer, in comparison to the standard of care, chemoradiation. In this study, participants will undergo a series of treatment visits during and after radiation therapy to assess the effectiveness of the experimental combination therapy.

Interventions

HPV vaccine, Imiquimod, and metformin combination therapy

Participants in the treatment arm will have visits during the 2nd and 4th weeks of radiation, and then at weeks 8, 10, 12, and 16 after radiation. At each visit, a blood sample will be taken, and tumor cells collected using a cytobrush (or directly from the tumor for vulvar cancer). An HPV vaccine will be injected into the tumor, imiquimod cream will be applied topically, and participants will receive a subcutaneous vaccine shot. They will also take metformin tablets twice daily for two weeks and apply imiquimod cream at home three nights per week. Follow-up PET/CT scans will occur at week 20 and two years post-treatment, with exams every three months for two years.

Primary outcome measure

  • Progression free survival [ Time Frame: 24 months ]

Central Contacts and Locations

Central contacts

Keneshia K Lane, B.A.

832-826-8071Keneshia.Lane@bcm.edu

Kathleen Pennington, Ph.D

832-824-4190kathleen.pennington@bcm.edu

Locations

Harris Health Smith Clinic

Recruiting

Houston, Texas, United States, 77054

Contacts

Keneshia K Lane, B.A

832-826-8071Keneshia.Lane@bcm.edu

Jan S Sunde, MD

206-778-9253sunde@bcm.edu

Principal Investigator:

Jan S Sunde, MD

More Information

Sponsor

Baylor College of Medicine

Last update posted

Nov 13, 2024

Last verified

Nov, 2024

Keywords

  • metformin
  • HPV
  • Imiquimod
  • Human Papillomavirus 9-valent Vaccine
  • Recombinant
  • Cytobrush
  • cervical cancer
  • vaginal cancer
  • vulvar cancer
  • chemoradiation
  • tumor
  • immunotherapy
  • metastatic
  • intratumoral
  • Endometrial cancer

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Baylor College of Medicine on 2024-11-13.